Where To Inject Wegovy: Injection Sites & Rotation

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists like semaglutide are administered via subcutaneous injection into specific body regions: the abdomen, thigh, or upper arm. Proper site selection and systematic rotation minimize injection-site reactions, reduce lipohypertrophy (fatty tissue buildup), and may support consistent drug absorption. Clinical guidelines emphasize rotating injection sites week to week to prevent tissue damage and local inflammatory responses.

Understanding injection technique is part of a larger precision-wellness conversation. For patients considering GLP-1 therapy, medical history, metabolic biomarkers, and genetic predispositions in peptide pathways all shape treatment response and tolerability. Your healthcare provider can help you develop a personalized administration plan aligned with your clinical profile and treatment goals.

Approved Injection Sites and Anatomical Landmarks

FDA-approved GLP-1 medications are administered via subcutaneous injection into three primary body regions. The abdomen (excluding the 2-inch area around the navel), the front and outer thigh, and the back of the upper arm are all acceptable sites. Each area offers a large subcutaneous tissue layer suitable for safe needle insertion and drug delivery.

Within each region, patients should choose a different spot each week. Injecting into the same location repeatedly increases risk of lipohypertrophy, scar tissue formation, and variable drug absorption. Healthcare providers recommend mentally dividing each injection area into quadrants and rotating systematically through them over four weeks before returning to the first site.

Site Rotation Protocol and Practical Administration Framework

A structured rotation schedule maximizes tissue health and supports consistent absorption kinetics. Below is a common four-week rotation framework that minimizes local tissue trauma and inflammatory responses at any single site.

Week	Injection Site	Specific Location	Clinical Rationale
Week 1	Abdomen	Upper right quadrant (2+ inches from navel)	Large subcutaneous layer; easy self-access
Week 2	Abdomen	Upper left quadrant (2+ inches from navel)	Allows right-side tissue recovery
Week 3	Thigh	Front outer surface, either leg	Alternative major site; distributes injection burden
Week 4	Upper arm	Back of arm between shoulder and elbow	Third major region; further tissue rest

Recognizing and Preventing Local Injection-Site Reactions

Common mild reactions include redness, swelling, and bruising at the injection site. These typically resolve within hours to days and are not dangerous. However, repeated injections in the same spot increase lipohypertrophy risk—visible fatty lumps under the skin that can impair drug absorption and create aesthetic concerns.

To prevent these reactions, allow at least one week between injections in the same anatomical area. Inspect injection sites regularly for lumps, discoloration, or persistent warmth. If reactions worsen or do not resolve within 48 hours, contact your healthcare provider. Proper technique—using room-temperature medication, pinching the skin slightly, and inserting the needle at a 90-degree angle—also reduces tissue trauma.

Safety Considerations and Who Should Verify Injection Technique with a Provider

Patients with bleeding disorders, those taking anticoagulants, or individuals with skin infections at potential injection sites should discuss technique and site selection with their healthcare provider before starting therapy. Skin infections, open wounds, or areas of lipohypertrophy should be avoided. Pregnant or breastfeeding patients should not use GLP-1 medications without explicit medical clearance.

Before your first injection, ask your provider or pharmacist to demonstrate proper technique. Many compounding pharmacies provide detailed instruction sheets and may offer video guidance. Incorrect injection depth, angle, or site selection can reduce drug efficacy and increase adverse events. A brief in-office or telehealth training session ensures you are confident and safe from the start.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your genetic predispositions in GLP-1 and GLP-2 receptor pathways, as well as factors like the MC4R and FTO genes that relate to appetite regulation and metabolic response. While genetics do not dictate injection technique, understanding your unique peptide pathway predispositions can support conversations with your provider about which GLP-1 medication formulation and dosing schedule may align best with your biology.

The genetic test reveals predispositions in peptide pathway variants (GLP1R rs6923761, GIPR rs1800437, MC4R rs17782313, and FTO rs9939609) that may influence how your body responds to GLP-1 therapy. This information should be interpreted with a qualified healthcare provider and is not a guarantee of medication efficacy or safety. Genetic context complements, not replaces, medical evaluation and clinical monitoring.

Combining proper injection technique with personalized biomarker and genetic insights can support a more informed conversation with your provider about medication selection, dosing, and monitoring frequency. PlexusDx compounded GLP-1 options (semaglutide injection, tirzepatide injection, or microdose protocols) paired with genetic predisposition data may help your provider tailor your treatment plan to your individual clinical profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I inject GLP-1 medication into the same spot every week?

No. Repeated injections in the same location increase risk of lipohypertrophy and may reduce drug absorption. Rotate sites systematically—abdomen, thigh, and upper arm—with at least one week between repeat injections in the same area.

What should I do if I develop a lump or thick area under my skin at an injection site?

Avoid injecting into that area for at least 4 weeks to allow healing. Lipohypertrophy typically resolves with rest. If lumps persist, enlarge, or become painful, contact your healthcare provider. They may evaluate for infection or tissue damage requiring medical attention.

How does PlexusDx support safe GLP-1 injection at home?

PlexusDx compounded semaglutide and tirzepatide injections are dispensed from licensed 503A pharmacies with detailed instruction materials. Your provider or pharmacist will review proper injection technique, site selection, and rotation before you begin therapy to ensure safe, effective administration.

Is it safe to inject GLP-1 if I take blood thinners or have a bleeding disorder?

Patients on anticoagulants or with bleeding disorders should notify their healthcare provider before starting GLP-1 therapy. While subcutaneous injection is generally safe, bleeding risk may be elevated. Your provider will assess whether injection therapy is appropriate and may recommend precautions or monitoring.

How does genetic testing relate to injection site reactions?

PlexusDx's Precision Peptide Genetic Test reveals predispositions in GLP-1 pathway genes, which may provide context for how your body responds to therapy overall. Injection-site reactions depend primarily on technique and rotation, not genetics. However, understanding your peptide pathway predisposition can inform personalized dosing and monitor...

Where To Inject Wegovy: Clinical Site Selection and Rotation Strategies